Literature DB >> 11893472

High CA 19-9 levels in benign biliary tract diseases. Report of four cases and review of the literature.

Konstantinos H. Katsanos1, Margarita Kitsanou, Dimitrios K. Christodoulou, Epameinondas V. Tsianos.   

Abstract

For years, CA 19-9 has been proposed as a marker for epithelial-type gastrointestinal cancers, even though it is well known that its diagnostic specificity is low. Here we describe cases of extremely high CA 19-9 levels in benign biliary tract diseases. The first case involved a 77-year-old male patient with choledocholithiasis and jaundice who was found to have CA 19-9 levels of 98,628 UI/ml. The second case was a 63-year-old male patient with autoimmune cholangitis and a CA 19-9 level of 250 IU/ml. The third case was a 74-year-old male patient with cholelithiasis and choledocholithiasis who developed acute cholangitis. CA 19-9 levels were elevated to 14,950 UI/ml during the episode. The fourth case involved a 73-year-old man with biliary colic and jaundice following an acute open cholecystectomy procedure who had a transient 100-fold increase in CA 19-9 (2230 IU/ml).

Entities:  

Year:  2002        PMID: 11893472     DOI: 10.1016/s0953-6205(02)00002-x

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  11 in total

1.  CA 19-9 to rule out pancreatic or biliary cancer among patients with cholestasis: an unsuitable test?

Authors:  Salvatore Madonia; Emma Aragona; Simonetta Maisano; Luigi Montalbano; Mirko Olivo; Francesca Rossi; Gaetano Restivo; Mario Cottone
Journal:  Dig Dis Sci       Date:  2007-03-07       Impact factor: 3.199

2.  Mirizzi's syndrome: a diagnostic dilemma.

Authors:  I N Masih; R J Moorehead; G R Caddy
Journal:  Ir J Med Sci       Date:  2009-04-15       Impact factor: 1.568

3.  Alpha1-and beta2-adrenoceptors in the human liver with mass-forming intrahepatic cholangiocarcinoma: density and coupling to adenylate cyclase and phospholipase C.

Authors:  W T Kassahun; B Günl; A Tannapfel; F R Ungemach; J Hauss; G Abraham
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-11-15       Impact factor: 3.000

4.  Elevated serum level of carbohydrate antigen 19-9 in benign biliary stricture diseases can reduce its value as a tumor marker.

Authors:  Mao-Song Lin; Jun-Xing Huang; Hong Yu
Journal:  Int J Clin Exp Med       Date:  2014-03-15

5.  Elevated serum CA 19-9 at screening tests: underlying conditions and role of abdominopelvic CT.

Authors:  Ji Yang Kim; Se Hyung Kim; Soo Young Kim
Journal:  Eur Radiol       Date:  2014-08-12       Impact factor: 5.315

6.  Prognostic Value of Preoperative Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 After Resection of Ampullary Cancer.

Authors:  Tobias S Schiergens; Bernhard W Renz; Simone Reu; Jens Neumann; Rami Al-Sayegh; Hanno Nieß; Matthias Ilmer; Stephan Kruger; Stefan Boeck; Volker Heinemann; Jens Werner; Axel Kleespies
Journal:  J Gastrointest Surg       Date:  2017-09-05       Impact factor: 3.452

7.  Hemobilia as the initial manifestation of cholangiocarcinoma in a hemophilia B patient.

Authors:  Anastassios-C Manolakis; Andreas-N Kapsoritakis; Antonis-D Tsikouras; Fotis-D Tsiopoulos; Athanassios-K Psychos; Spyros-P Potamianos
Journal:  World J Gastroenterol       Date:  2008-07-14       Impact factor: 5.742

8.  The diagnostic value of brush cytology alone and in combination with tumor markers in pancreaticobiliary strictures.

Authors:  Ufuk Barış Kuzu; Bülent Ödemiş; Nesrin Turhan; Erkan Parlak; Selçuk Dişibeyaz; Nuretdin Suna; Erkin Öztaş; Muhammet Yener Akpınar; Adem Aksoy; Serkan Torun; Hakan Yıldız; Ertuğrul Kayaçetin
Journal:  Gastroenterol Res Pract       Date:  2015-03-26       Impact factor: 2.260

9.  Benign Hydronephrosis and Elevated of Serum Levels of Carbohydrate Antigen CA 19-9: A Case Report.

Authors:  Branka Filipovic; Nikola Milinić; Jasna Gacic; Olivera Markovic; Aleksandra Djokovic; Branislav Filipovic
Journal:  Am J Case Rep       Date:  2016-06-11

10.  Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9.

Authors:  Roman O Kowalchuk; Scott C Lester; Rondell P Graham; William S Harmsen; Lizhi Zhang; Thorvardur R Halfdanarson; Rory L Smoot; Hunter C Gits; Wen Wee Ma; Dawn Owen; Amit Mahipal; Robert C Miller; Michelle A Neben Wittich; Sean P Cleary; Robert R McWilliams; Michael G Haddock; Christopher L Hallemeier; Mark J Truty; Kenneth W Merrell
Journal:  Front Oncol       Date:  2021-05-11       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.